Literature DB >> 23294372

In vitro synergy of oxacillin and gentamicin against coagulase-negative staphylococci from blood cultures of neonates with late-onset sepsis.

Tatjana Brilene1, Hiie Soeorg, Merilin Kiis, Epp Sepp, Siiri Kõljalg, Krista Lõivukene, Marika Jürna-Ellam, Jelena Kalinina, Jelena Stšepetova, Tuuli Metsvaht, Irja Lutsar.   

Abstract

Coagulase-negative staphylococci (CoNS) are the leading cause of late-onset sepsis (LOS) in neonates. Increasing resistance of CoNS to beta-lactams and aminoglycosides has led to widespread use of vancomycin, which in turn may lead to resistance to vancomycin. Thus, combination therapy of LOS has been advocated. We aimed to determine the interaction of oxacillin and gentamicin against CoNS. In 2005, 34 isolates of oxacillin- and gentamicin-resistant CoNS were obtained from blood samples of neonates with LOS. Combination effect was tested using the checkerboard method, E-test with the other antibiotic incorporated in the medium (E-test-1) and two E-test strips placed in a cross-formation (E-test-2). Of 34 isolates 61.8%, 53% and 73.5% revealed synergy or an additive effect when tested by the checkerboard method, E-test-1 and E-test-2, respectively. Results of all three tests were concordant for six (17.6%) isolates, four showing synergy, and two indifference. Our in vitro results support that combination therapy with penicillinase-resistant penicillin and aminoglycoside can be an alternative to vancomycin.
© 2013 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  In vitro synergy; coagulase-negative staphylococci; gentamicin; oxacillin

Mesh:

Substances:

Year:  2013        PMID: 23294372     DOI: 10.1111/apm.12048

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  5 in total

1.  Pharmacokinetics of regional limb perfusion using a combination of amikacin and penicillin in standing horses.

Authors:  Roee Dahan; Gil L Oreff; Amos J Tatz; Tal Raz; Malka Britzi; Gal Kelmer
Journal:  Can Vet J       Date:  2019-03       Impact factor: 1.008

2.  Epidemiological Evaluation of Blood Culture Patterns among Neonates Receiving Vancomycin.

Authors:  Salman Y Yakub; Jonathan E Constance; Chris Stockmann; Matthew Linakis; Sarah C Campbell; Catherine M T Sherwin; Ernest K Korgenski; Alfred Balch; Michael G Spigarelli
Journal:  Indian J Microbiol       Date:  2014-06-17       Impact factor: 2.461

Review 3.  Neonatal sepsis due to coagulase-negative staphylococci.

Authors:  Elizabeth A Marchant; Guilaine K Boyce; Manish Sadarangani; Pascal M Lavoie
Journal:  Clin Dev Immunol       Date:  2013-05-22

4.  Efficacy of neutral and negatively charged liposome-loaded gentamicin on planktonic bacteria and biofilm communities.

Authors:  Moayad Alhariri; Majed A Majrashi; Ali H Bahkali; Faisal S Almajed; Ali O Azghani; Mohammad A Khiyami; Essam J Alyamani; Sameera M Aljohani; Majed A Halwani
Journal:  Int J Nanomedicine       Date:  2017-09-18

5.  An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial.

Authors:  Louise F Hill; Mark A Turner; Irja Lutsar; Paul T Heath; Pollyanna Hardy; Louise Linsell; Evelyne Jacqz-Aigrain; Emmanuel Roilides; Mike Sharland
Journal:  Trials       Date:  2020-04-15       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.